Transgene receives FDA IND Clearance for Lead myvac® Individualized Immunotherapy, TG4050, to Commence Clinical Development in Ovarian Cancer

20190513 PR IND TG4050 EN

Transgene sa
400 Boulevard Gonthier d’Andernach - Parc d'Innovation - CS80166
67405 Illkirch Graffenstaden Cedex - France |
Tel. : + 33 (0) 3 88 27 91 00

 

© 2021 Transgene - All rights reserved
Terms of use - Credits